Goldman Sachs
KRTX

Goldman Sachs’s Karuna Therapeutics, Inc. Common Stock KRTX Stock Holding History

Goldman Sachs’s Portfolio KRTX Stock Details KRTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q1 		– Sell
-15,000
Closed -$1.97M – 7000
2021
Q4 		$1.97M Hold
15,000
– – ﹤0.01% 4267
2021
Q3 		$1.83M Buy
+15,000
New +$1.73M ﹤0.01% 4276

Other funds holding KRTX

IA
IFP Advisors Tampa, Florida $5.54B AUM 27.43% 1-Year Est. Return
S
Sachetta Lynnfield, Massachusetts $206M AUM 26.19% 1-Year Est. Return

Goldman Sachs's KRTX Position: Q1 2024 in Review

Goldman Sachs sold out of Karuna Therapeutics, Inc. Common Stock (KRTX) in Q1 2024, closing a stake of 201,270 shares — an estimated $63.7M sold.

Goldman Sachs first reported a position in KRTX in Q2 2019 and held it in 18 quarters. The position peaked at $63.7M in Q4 2023. 2 funds tracked by Wall St. Rank hold KRTX as of Q1 2024.

  • Goldman Sachs reported no remaining Karuna Therapeutics, Inc. Common Stock position as of Q1 2024 after selling out during the quarter.
  • Goldman Sachs sold 201,270 Karuna Therapeutics, Inc. Common Stock shares in Q1 2024, an estimated $63.7M.
  • Goldman Sachs first reported a position in Karuna Therapeutics, Inc. Common Stock in Q2 2019 and held it in 18 quarters.
  • Goldman Sachs's Karuna Therapeutics, Inc. Common Stock position peaked at $63.7M in Q4 2023.
  • 2 funds tracked by Wall St. Rank held Karuna Therapeutics, Inc. Common Stock as of Q1 2024.

Based on Goldman Sachs's 13F filing for Q1 2024, filed 15 May 2024.